top of page


(selected from last 12 years)

Mitra, R., C. M. Adams, W. Jiang, E. Greenawalt, and C. M. Eischen. Pan-cancer analysis reveals cooperativity of both strands of microRNA that regulate tumorigenesis and patient survival. Nature Communications 11(1):968, 2020.


Adams, C. M., R. Mitra, A. N. Vogel, J. Liu, J. Z. Gong, and C. M. Eischen. Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma. Leukemia 34(3):947-952, 2020.

Thomas, L.R., C. M. Adams, J. Wang, A. M. Weissmiller, J. Creighton, S. L. Lorey, Q Liu, S. W. Fesik, C. M. Eischen, and W. P. Tansey. Interaction of the oncoprotein transcription factor MYC with its chromatin co-factor WDR5 is essential for tumor maintenance. Proc Natl Acad Sci USA 116(50):25260-25268, 2019.


Stier, M. T., R. Mitra, L. E. Nyhoff, K. Goleniewska, J. Zhang, M. V. Puccetti, H. C. Casanova, A. C. Seegmiller, P. J. Bryce, D. Newcomb, P. L. Kendall, C. M. Eischen*, R. S. Peebles*. IL-33 is cell-intrinsic regulator of fitness during early B cell development.  J. of Immunology 203(6):1457-1467, 2019. *co-corresponding authors

Puccetti, M. V., C. M. Adams, T. D. Dan, A. Palagani, B. A. Simone, T. DeAngelis, C. M. Eischen*, and N. L. Simone*. miR-21 is required for hematopoietic cell viability following radiation exposure. International Journal of Radiation Oncology Biology Physics 104(5):1165-1174, 2019. *co-corresponding authors


Puccetti, M. V., C. M. Adams, S. Kushinsky, and C. M. Eischen. Smarcal1 and Zranb3 protect replication forks from Myc-induced DNA replication stress. Cancer Research 79(7):1612-1623, 2019. (Our fiber labeling picture selected for cover and a review written by Dr. Thanos Halazonetis accompanied this publication)


Greenawalt, E.J., M. D. Edmonds, N. Jain, C. M. Adams, R. Mitra, and C. M. Eischen. Targeting of SGK1 by miR-576-3p inhibits lung adenocarcinoma migration and invasion. Molecular Cancer Research 17(1):289-298, 2019.

Mitra, R., X. Chen, U. Maulik, W. Jiang, Z. Zhao, and C. M. Eischen. Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition. Nature Communications 8(1):1604, 2017. (Highlighted by Science Daily and Medical Press)


Adams*, C. M., R. Mitra*, J. Z. Gong, and C. M. Eischen. Non-Hodgkin and Hodgkin lymphomas select for overexpression of BCLW. Clinical Cancer Research 23(22):7119-7129, 2017. (Findings reported by AACI). *co-first authors


Feeley, K. P., C. M. Adams, R. Mitra, and C. M. Eischen. Mdm2 is required for survival and growth of p53-deficient cancer cells. Cancer Research 77(14):3823-3833, 2017. (Findings reported by AACI)


Moyo, T. K., C. S. Wilson, D. J. Moore, and C. M. Eischen. Myc enhances B cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition. Oncogene 36(32):4653-4661, 2017.


Adams, C. M., A. S. Kim, R. Mitra, J. K. Choi, J. Z. Gong, and C. M. Eischen. BCL-W has a fundamental role in B cell survival and lymphomagenesis. J. Clinical Investigation 127(2):635-650, 2017. (Findings reported by OncLive, Oncology Times, and a commentary in Cancer Discovery)


Puccetti, M. V., M. A. Fischer, M. P. Arrate, K. L. Boyd, R. J. Duszynski, R. Bétous, D. Cortez, and C. M. Eischen. Defective replication stress response inhibits T-cell lymphomagenesis and impairs lymphocyte reconstitution. Oncogene 36(18):2553-2564, 2017. (Findings reported by Human Immunology News)


Oran, A.R., C. M. Adams, X-Y Zhang, V. J. Gennaro, H. K. Pfeiffer, H. S. Mellert, H. E. Seidel, Ki. Mascioli, J. Kaplan, M. R. Gaballa, C. Shen, I. Rigoutsos, M. P. King, J. Cotney, J. J. Arnold, S. D. Sharma, U. E. Martinez-Outschoorn, C. R. Vacok, L. A. Chodosh, J. A. Thompson, J. E. Bradner, C. E. Cameron, G. S. Shadel, C. M. Eischen, and S. B. McMahon. Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer. Oncotarget 7(45):72395-72414, 2016.


Liu, S., R. Mitra, M. Zhao, W. Fan, C. M. Eischen, F. Yin, Z. Zhao. The potential roles of long non-coding RNAs (lncRNAs) in glioblastoma development. Molecular Cancer Therapeutics 15(12): 2977-2986, 2016.


Grieb, B.C., K. Boyd, R. Mitra, and C. M. Eischen. Haploinsufficiency of the Myc Regulator Mtbp Extends Survival and Delays Tumor Development in Aging Mice. Aging 8(10):2590-2602, 2016.


Adams, CM and C. M. Eischen. Histone deacetylase inhibition reveals a tumor suppressive function of MYC-regulated miRNA in breast and lung carcinoma. Cell Death & Diff 23(8):1312-21, 2016.


Thomas, L.R., A. M. Foshage, A. M. Weissmiller, T. M. Popay, B. C. Grieb, S. Qualls, V. Ng, B. Carboneau, S. Lorey, C. M. Eischen, and W. P. Tansey.  Interaction of MYC with Host Cell Factor 1 is meditated by the evolutionarily-conserved Myc box IV motif. Oncogene 35(27):3613-8, 2016.

Adams, C. M., S. W. Hiebert, and C. M. Eischen. Myc induces miRNA-mediated apoptosis in response to HDAC inhibition in hematological malignancies. Cancer Research 76(3):736-48, 2016.


Edmonds, M.D., K. L. Boyd, T. Moyo, R. Mitra, R. Duszynski, M. P.Arrate, X. Chen, Z. Zhao, T. S. Blackwell, T. Andl, and C. M. Eischen.  miR-31 initiates lung tumorigenesis and promotes mutant KRas-driven lung cancer. J. Clinical Investigation 126(1):349-64, 2016.


Poole, L. A., R. Zhao, C. A. Lovejoy, C. M. Eischen, and D. Cortez. ­­­­­­­­­SMARCAL1 maintains telomere integrity during DNA replication. Proc Natl Acad Sci USA 112(48):14864-9, 2015.


Tonsing-Carter, E., B. J. Bailey, M. R. Saadatzadeh, J. Ding, H. Wang, A. L. Sinn, K. M. Peterman, T. K. Spragins, J. M. Silver, A. A. Sprouse, T. M. Georgiadis, T. Z. Gunter, E. C. Long, R. E. Minto, C. C. Marchal, C. N. Batuello, A. R. Safa, H. Hanenberg, P. R. Territo, G. E. Sandusky, L. D. Mayo, C. M. Eischen, H. E. Shannon, and K.E. Pollok. Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model. Molecular Cancer Therapeutics 14(12):2850-63, 2015.


McGirt, L.Y., P. Jia, D. A. Baerenwald, R. J. Duszynski, K. B. Dahlman, J. A. Zic, J. P. Zwerner, D. Hucks, U. Dave, Z. Zhao, and C. M. Eischen.  Whole genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood 126(4):508-19, 2015.


Carrillo, A. M, M. Hicks, D. Khabele, and C. M. Eischen. Pharmacologically increasing Mdm2 inhibits DNA repair and cooperates with genotoxic agents to kill p53 inactivated ovarian cancer cells. Molecular Cancer Research 13(8):1197-205, 2015.  (Highlighted in journal)


Mitra, R., C-C Lin, C. M. Eischen, S. Bandyopadhyay, and Z. Zhao. Concordant dysregulation of miR-5p and miR-3p arms of the same precursor microRNA may be a mechanism in inducing cell proliferation and tumorigenesis: A lung cancer study. RNA 21(6):1055-65, 2015.


Thomas, L. R., Q. Wang, B. C. Grieb, J. Phan, A. M. Foshage, Q. Sun, E. T. Olejniczak, T. Clark, S. Dey, S. Lorey, G. C. Howard, B. Cawthon, K. C. Ess, C. M. Eischen, Z. Zhao, S. W. Fesik, and W. P. Tansey. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Molecular Cell 58(3):440-52, 2015.


Carrillo, A.M., A. Bouska, M. P. Arrate, and C. M. Eischen. Mdmx promotes genomic instability independent of p53 and Mdm2. Oncogene 34(7):846-56, 2015.

Mitra, R., M. Edmonds, J. Sun, M. Zhao, H Yu, C. M. Eischen, and Z. Zhao. Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer. RNA 20(9):1356-68, 2014.


Grieb, B.C., X. Chen, and C. M. Eischen. MTBP is overexpressed in triple negative breast cancer and contributes to its growth and survival. Molecular Cancer Research 12(9):1216-24, 2014. (Highlighted by the NIH/NCI and The Cancer Genome Atlas)


Adams, C. M. and C. M. Eischen. Inactivation of p53 is insufficient to allow B cells and B cell lymphomas to survive without Dicer. Cancer Research 15;74(14):3923-34, 2014.


Edmonds, M.D. and C. M. Eischen. Differences in miRNA Expression in Early Stage Lung Adenocarcinomas that Did and Did Not Relapse. PLOS ONE 9(7):e101802, 2014.


Grieb, B.C., M.W. Gramling, M.P. Arrate, X. Chen, S.L. Beauparlant, D.S. Haines, H. Xiao, C. M. Eischen. Oncogenic protein MTBP interacts with MYC to promote tumorigenesis. Cancer Research 74(13):3591-602, 2014.


McGirt, L. Y. C. M. Adams, D.A. Baerenwald, Jeffrey P. Zwerner, J.A. Zic, C. M. Eischen. miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma. J. of Investigative Dermatology 134(4):1101-7, 2014.

Eischen, C. M.* and K. Boyd.  Decreased Mdm2 expression inhibits tumor development and extends survival independent of Arf and dependent on p53. PLoS ONE 7(9):e46148, 2012.    *corresponding author


Anderson, P.D., S. A. McKissic, M. Logan, M. Roh, O. E. Franco, J. Wang, I. Doubinskaia, R. van der Meer, S. W. Hayward, C. M. Eischen, I-E Eltoum, and S. A.  Abdulkadir. Nkx3.1 and c-Myc Cross-regulate Shared Target Genes in Mouse and Human Prostate Tumorigenesis. J. Clinical Invest 122(5):1907-19, 2012.


Gramling, M. W. and C. M. Eischen. Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis. Cell Death & Differentiation 19(7):1220-1227, 2012.


Lushnikova, T., A. Bouska, J. Odvody, W. D. Dupont, and C. M. Eischen. Aging mice have increased chromosome instability that is exacerbated by elevated Mdm2 expression. Oncogene 30(46):4622-31, 2011.


Cho, S. H., A. Ahn, P. Bhargava, C-H. L., C. M. Eischen, O. McGuinness, and M. Boothby.  Glycolytic rate and lymphomagenesis depend on PARP14, an ADP-ribosyltransferase of the B Aggressive Lymphoma (BAL) family. Proc Natl Acad Sci 108(38):15972-7, 2011. 


Arrate, P.M., T. Vincent, J. Odvody, R. Kar, S. N. Jones, and C. M. Eischen.  MicroRNA Biogenesis is Required for Myc-Induced B cell Lymphoma Development and Survival. Cancer Research 70(14):6083-6092, 2010.  


Odvody, J., T. Vincent, M. P. Arrate, B. Grieb, S. Wang, J. Garriga, G. Lozano, T.  Iwakuma, D. S. Haines, and C. M. Eischen.  A deficiency in Mdm2 binding protein (MTBP) inhibits Myc-induced B cell proliferation and lymphomagenesis. Oncogene 29(22):3287-3296, 2010.


Sluss, H. K., H. Gannon, H. Coles, Q. Shen, A., C. M. Eischen, and S. N. Jones. Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis. Molecular Cancer Research 8(2):216-222, 2010.


Post, S. M., A. Quintas-Cardama, T. Terzian, C. Smith, C. M. Eischen, and G. Lozano.  p53-Dependent Senescence Delays Em-myc-Induced B-cell Lymphomas. Oncogene 29(9):1260-1269, 2009.


Cho S. H., S. Goenka, T. Henttinen, P. Gudapati, A. Reinikainen, C. M. Eischen, R. Lahesmaa, and M. Boothby. PARP-14, a member of the B aggressive lymphoma (BAL) family, transduces survival signals in primary B cells.  Blood 113(11):2416-2425, 2009.

bottom of page